Clinical experience with a tiered-therapy, multiprogrammable antiarrhythmia device.

Bardy, Gust H.; Troutman, Charles; Poole, Jeanne E.; Kudenchuk, Peter J.; Dolack, G. Lee; Johnson, George; Hofer, Bradley O.

doi:10.1161/01.cir.85.5.1689

Cited by 134 publications

(26 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1,2 In addition to increasing the possibility of inappropriate ventricular shocks, atrial tachyarrhythmias may also increase the risk of heart failure 3 and stroke. 4 Drug therapy for atrial tachyarrhythmias in patients with ICDs is often unsatisfactory due to limited drug efficacy and ventricular proarrhythmia.…”

mentioning

confidence: 99%

Efficacy of Pacing Therapies for Treating Atrial Tachyarrhythmias in Patients With Ventricular Arrhythmias Receiving a Dual-Chamber Implantable Cardioverter Defibrillator

Adler

Wolpert²,

Warman³

et al. 2001

Circulation

View full text Add to dashboard Cite

for the Worldwide Jewel AF Investigators Background-Although overdrive pacing for treating atrial flutter is well established, the efficacy of device-based atrial pacing for treating spontaneous atrial tachyarrhythmias in patients with implantable cardioverter defibrillators (ICD) is unknown. This study evaluated the efficacy of novel pacing therapies for treating atrial tachyarrhythmias in patients receiving a dual-chamber ICD to treat ventricular tachyarrhythmias. Methods and Results-A Jewel AF ICD was implanted in 537 patients with ventricular arrhythmia who were followed for 11.4Ϯ8.2 months (74% had a documented history of atrial tachyarrhythmias). The device discriminated atrial tachycardia (AT) from atrial fibrillation (AF) on the basis of cycle length and regularity, and it used 3 different methods of overdrive atrial pacing (Ramp, Burstϩ, and 50-Hz burst) to treat AT episodes and one method (50-Hz burst) to treat AF episodes. Pacing successfully terminated 59% of 1500 spontaneous AT episodes in 127 patients and 30% of 880 AF episodes in 101 patients (PϽ0.001). With AT and AF episodes combined, pacing efficacy was 48%. Pacing efficacy was significantly reduced at AT cycle lengths Յ220 ms and AF cycle lengths Յ160 ms (PϽ0.01) The median time from pacing to AT/AF termination was 1.1 minute for the pacing successes and 96 minutes for the failures (PϽ0.001). Conclusions-Atrial

show abstract

mentioning

confidence: 99%

Efficacy of Pacing Therapies for Treating Atrial Tachyarrhythmias in Patients With Ventricular Arrhythmias Receiving a Dual-Chamber Implantable Cardioverter Defibrillator

Adler

Wolpert²,

Warman³

et al. 2001

Circulation

View full text Add to dashboard Cite

show abstract

“…Thus, because of the range of ATP options available and the clinical limitations of repetitive inductions of VT, the question was examined for only one particular form of ATP, overdrive decremental antitachycardia pacing, previously demonstrated to be effective. 5,6 Methods After giving informed consent, 24 patients with a tiered therapy antiarrhythmia device (Medtronic 7217B PCD) were enrolled in a prospective randomized, repeat-crossover comparison of ATP to LEC for the treatment of monomorphic VT.…”

mentioning

confidence: 99%

A prospective randomized repeat-crossover comparison of antitachycardia pacing with low-energy cardioversion.

et al. 1993

Self Cite

View full text Add to dashboard Cite

show abstract

“…The ICD, on the other hand, was shown to be an effective therapy for treating patients resuscitated from out of hospital ventricular fibrillation (VF) or syncopal ventricular tachycardia [1][2][3]16] and in an early trial examining the role of the ICD as a primary prevention strategy in a select high-risk group of patients with CAD (MADIT) [5].…”

Section: Review Of Scd-heft Trial Designmentioning

confidence: 99%

New indications for implantable defibrillator therapy

Poole

2006

Curr Cardiol Rep

View full text Add to dashboard Cite

Implantable cardioverter defibrillator (ICD) therapy has been extensively evaluated in patients at high risk of sudden cardiac death. Most recently, the Sudden Cardiac Death in Heart Failure Trial found that patients with moderate symptoms of congestive heart failure, whether due to an ischemic or a nonischemic cause, have reduced mortality compared with patients treated only with conventional medical therapy for heart failure. The results of this trial confirm those of earlier trials finding a benefit of ICD therapy in patients with coronary artery disease and reduced left ventricular systolic function, and extend the indications for ICD therapy to those without coronary artery disease.

show abstract

Clinical experience with a tiered-therapy, multiprogrammable antiarrhythmia device.

Cited by 134 publications

References 36 publications

Efficacy of Pacing Therapies for Treating Atrial Tachyarrhythmias in Patients With Ventricular Arrhythmias Receiving a Dual-Chamber Implantable Cardioverter Defibrillator

Efficacy of Pacing Therapies for Treating Atrial Tachyarrhythmias in Patients With Ventricular Arrhythmias Receiving a Dual-Chamber Implantable Cardioverter Defibrillator

A prospective randomized repeat-crossover comparison of antitachycardia pacing with low-energy cardioversion.

New indications for implantable defibrillator therapy

Contact Info

Product

Resources

About